OptimizeRx’s (OPRX) “Buy” Rating Reaffirmed at Roth Mkm

OptimizeRx (NASDAQ:OPRX)‘s stock had its “buy” rating reissued by equities researchers at Roth Mkm in a report released on Thursday,Benzinga reports. They currently have a $16.00 price target on the stock, down from their prior price target of $20.00. Roth Mkm’s price objective would indicate a potential upside of 262.81% from the stock’s current price.

A number of other equities research analysts have also recently commented on the company. Royal Bank of Canada decreased their price objective on OptimizeRx from $17.00 to $14.00 and set an “outperform” rating for the company in a research note on Friday, August 16th. JMP Securities lowered their price target on OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a research note on Thursday. Stifel Nicolaus cut their price target on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday. Barclays decreased their price objective on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a report on Thursday. Finally, B. Riley assumed coverage on shares of OptimizeRx in a research report on Thursday, July 25th. They set a “buy” rating and a $18.50 price target on the stock. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.58.

OptimizeRx Trading Down 28.3 %

Shares of NASDAQ OPRX traded down $1.74 during midday trading on Thursday, hitting $4.41. The stock had a trading volume of 538,045 shares, compared to its average volume of 134,035. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.07 and a quick ratio of 3.07. OptimizeRx has a fifty-two week low of $4.27 and a fifty-two week high of $16.65. The firm has a market cap of $80.80 million, a P/E ratio of -4.41 and a beta of 1.32. The company’s 50-day simple moving average is $6.75 and its 200 day simple moving average is $9.07.

Institutional Trading of OptimizeRx

Institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its position in OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after buying an additional 2,414 shares in the last quarter. Quest Partners LLC boosted its holdings in shares of OptimizeRx by 15,965.6% in the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after buying an additional 9,739 shares during the last quarter. Greenwood Capital Associates LLC grew its stake in shares of OptimizeRx by 8.0% in the third quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock valued at $520,000 after buying an additional 4,999 shares in the last quarter. Janney Montgomery Scott LLC acquired a new position in OptimizeRx during the third quarter worth $810,000. Finally, Rice Hall James & Associates LLC lifted its stake in OptimizeRx by 24.0% in the third quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock valued at $4,751,000 after acquiring an additional 119,306 shares during the last quarter. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.